AptaBio Therapeutics Past Earnings Performance
Past criteria checks 0/6
AptaBio Therapeutics's earnings have been declining at an average annual rate of -51.8%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been growing at an average rate of 5430.6% per year.
Key information
-51.8%
Earnings growth rate
-50.5%
EPS growth rate
Biotechs Industry Growth | 11.7% |
Revenue growth rate | 5,430.6% |
Return on equity | -41.5% |
Net Margin | -694.0% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
AptaBio Therapeutics (KOSDAQ:293780) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 29Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?
Jul 12Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money
Mar 26Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?
Feb 23Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth
Jan 01Revenue & Expenses Breakdown
How AptaBio Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 2,906 | -20,170 | 5,542 | 13,933 |
30 Jun 24 | 2,055 | -16,236 | 3,783 | 13,933 |
31 Mar 24 | 942 | -11,012 | 2,693 | 14,019 |
31 Dec 23 | 324 | -11,867 | 3,915 | 12,380 |
30 Sep 23 | 53 | -13,289 | 3,626 | 9,240 |
31 Dec 22 | 48 | -10,565 | 2,788 | 6,197 |
Quality Earnings: A293780 is currently unprofitable.
Growing Profit Margin: A293780 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if A293780's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare A293780's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A293780 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).
Return on Equity
High ROE: A293780 has a negative Return on Equity (-41.45%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/27 11:02 |
End of Day Share Price | 2024/12/27 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AptaBio Therapeutics Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Taehee Kim | Mirae Asset Securities Co., Ltd. |
Keunhee Seo | Samsung Securities Co. Ltd. |